(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the Euronext session.

The three biggest winners today are PCI BIOTECH HOLD, NORTHERN DRILLING, and BERGENBIO.

Financial Asset	Price	Change	Updated (EST)
PCI BIOTECH HOLD (PCIB.OL)	2.71	29.67%	2023-10-16 12:42:01
NORTHERN DRILLING (NODL.OL)	3.69	19.03%	2023-10-16 12:41:29
BERGENBIO (BGBIO.OL)	0.14	14.47%	2023-10-16 12:24:47
LAVIDE HOLDING (LVIDE.AS)	0.23	11.65%	2023-10-16 12:02:42
DIEGEM KENNEDYCERT (DIEG.BR)	116.00	9.43%	2023-10-16 12:05:37
ABIONYX PHARMA (ABNX.PA)	1.24	8.74%	2023-10-16 12:44:25
IDEX BIOMETRICS (IDEX.OL)	0.52	8.13%	2023-10-16 12:40:32
TEKNA HOLDING (TEKNA.OL)	6.92	8.12%	2023-10-16 12:43:39
EBUSCO HOLDING (EBUS.AS)	6.47	6.94%	2023-10-16 12:01:41
HAVILA SHIPPING (HAVI.OL)	9.60	5.26%	2023-10-16 12:40:21

The three biggest losers today are CABKA, ATLANTIC SAPPHIRE, and NAPATECH.

Financial Asset	Price	Change	Updated (EST)
CABKA (CABKA.AS)	7.06	-8.07%	2023-10-16 12:01:11
ATLANTIC SAPPHIRE (ASA.OL)	1.63	-7.47%	2023-10-16 12:24:32
NAPATECH (NAPA.OL)	11.25	-7.41%	2023-10-16 12:41:12
ADOCIA (ADOC.PA)	7.51	-6.24%	2023-10-16 12:44:43
LINK MOBILITY GRP (LINK.OL)	12.02	-4.91%	2023-10-16 12:40:58
PHOTOCURE (PHO.OL)	58.10	-4.75%	2023-10-16 12:42:10
OCEANTEAM (OTS.OL)	1.45	-4.61%	2023-10-16 12:41:41
IEP INVEST (IEP.BR)	5.45	-4.39%	2023-10-16 12:20:14
MITHRA (MITRA.BR)	1.10	-4.2%	2023-10-16 12:20:41
SEQUANA MEDICAL (SEQUA.BR)	2.53	-4.17%	2023-10-16 12:21:19

Winners today

1. PCI BIOTECH HOLD (PCIB.OL)

29.67% Price Change

PCI Biotech Holding ASA, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of cancer through its photochemical internalization (PCI) technology platform. The company develops anticancer paradigms, including fimaCHEM, a chemotherapeutics for treatment of cancer; fimaVACC, a T-cell induction technology for therapeutic vaccination, which is in pre-clinical study; and fimaNAc, a nucleic acid therapeutics delivery technology, which is in pre-clinical study. It also offers Amphinex, a photosensitiser fimaporfin. The company has collaborative research programs with Olix Pharmaceuticals, Aposense, IMV Immunovaccine, MDimune, eTheRNA, and Immunicum. PCI Biotech Holding ASA was incorporated in 2007 and is based in Oslo, Norway.

Oslo Børs Benchmark Index_GI ended the session with PCI BIOTECH HOLD jumping 29.67% to €2.71 on Monday while Oslo Børs Benchmark Index_GI jumped 0.09% to €1,312.00.

Earnings Per Share

As for profitability, PCI BIOTECH HOLD has a trailing twelve months EPS of kr-1.22.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -47.54%.

Yearly Top and Bottom Value

PCI BIOTECH HOLD’s stock is valued at kr2.71 at 22:40 EST, way under its 52-week high of kr5.93 and way above its 52-week low of kr1.20.

Volatility

PCI BIOTECH HOLD’s last week, last month’s, and last quarter’s current intraday variation average was 13.61%, 2.10%, and 4.33%.

PCI BIOTECH HOLD’s highest amplitude of average volatility was 17.61% (last week), 5.46% (last month), and 4.33% (last quarter).

Earnings Before Interest, Taxes, Depreciation, and Amortization

PCI BIOTECH HOLD’s EBITDA is -4.54.

More news about PCI BIOTECH HOLD.

2. NORTHERN DRILLING (NODL.OL)

19.03% Price Change

Northern Drilling Ltd. operates as an offshore drilling contractor to the oil and gas industry. The company primarily engages in acquiring and operating offshore drilling assets, as well as involved in drilling in ultra-deep water environments. Northern Drilling Ltd. was incorporated in 2017 and is based in Hamilton, Bermuda.

Oslo Børs Benchmark Index_GI ended the session with NORTHERN DRILLING jumping 19.03% to €3.69 on Monday while Oslo Børs Benchmark Index_GI rose 0.09% to €1,312.00.

Earnings Per Share

As for profitability, NORTHERN DRILLING has a trailing twelve months EPS of kr-5.47.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -4.22%.

Moving Average

NORTHERN DRILLING’s value is way under its 50-day moving average of kr20.66 and way under its 200-day moving average of kr27.18.

More news about NORTHERN DRILLING.

3. BERGENBIO (BGBIO.OL)

14.47% Price Change

BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in development of novel medicines to treat immune-evasive, drug resistant, and metastatic cancers; and respiratory diseases. It develops bemcentinib, an oral once-a-day inhibitor of AXL receptor tyrosine kinase, which is in Phase 1b/2a clinical trial to treat non-small cell lung cancer, and Phase 2 clinical trial to treat acute myeloid leukemia and COVID-19. Bemcentinib is also being studied for glioblastoma, 2L lung cancer, melanoma, pancreatic cancer, and mesothelioma. In addition, the company is developing tilvestamab, an anti-AXL function-blocking monoclonal antibody that is in Phase 1b clinical trial for the treatment of ovarian cancer; and mipasetamab uzoptirine, which is in Phase 1 clinical trial for the treatment of solid tumors. It has a collaboration agreement with Merck & Co. for clinical trials. The company was incorporated in 2007 and is based in Bergen, Norway.

Oslo Børs Benchmark Index_GI ended the session with BERGENBIO rising 14.47% to €0.14 on Monday, after two successive sessions in a row of losses. Oslo Børs Benchmark Index_GI rose 0.09% to €1,312.00, after two successive sessions in a row of gains, on what was a somewhat bullish trend exchanging session today.

Earnings Per Share

As for profitability, BERGENBIO has a trailing twelve months EPS of kr-1.59.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -179.58%.

Moving Average

BERGENBIO’s value is way above its 50-day moving average of kr0.13 and way below its 200-day moving average of kr4.18.

Volatility

BERGENBIO’s last week, last month’s, and last quarter’s current intraday variation average was 1.95%, 0.23%, and 4.93%.

BERGENBIO’s highest amplitude of average volatility was 7.42% (last week), 3.81% (last month), and 4.93% (last quarter).

More news about BERGENBIO.

4. LAVIDE HOLDING (LVIDE.AS)

11.65% Price Change

Lavide Holding N.V. does not have significant operations. Previously, it was engaged in the provision of integrated information technology solutions for medium to large-sized companies and organizations. The company was formerly known as Qurius N.V. and changed its name to Lavide Holding N.V. in July 2013. Lavide Holding N.V. was incorporated in 1998 and is based in Sluis, the Netherlands.

AEX-Index ended the session with LAVIDE HOLDING jumping 11.65% to €0.23 on Monday, following the last session’s downward trend. AEX-Index rose 0.2% to €735.39, following the last session’s downward trend on what was a somewhat positive trend exchanging session today.

Earnings Per Share

As for profitability, LAVIDE HOLDING has a trailing twelve months EPS of €-0.04.

Yearly Top and Bottom Value

LAVIDE HOLDING’s stock is valued at €0.23 at 22:40 EST, way under its 52-week high of €0.51 and way higher than its 52-week low of €0.14.

More news about LAVIDE HOLDING.

5. DIEGEM KENNEDYCERT (DIEG.BR)

9.43% Price Change

Immolease Trust NV operates as a subsidiary of KBC Bank NV.

BEL 20 ended the session with DIEGEM KENNEDYCERT jumping 9.43% to €116.00 on Monday, after five sequential sessions in a row of losses. BEL 20 jumped 0.31% to €3,518.40, after two consecutive sessions in a row of losses, on what was a somewhat bullish trend trading session today.

Volatility

DIEGEM KENNEDYCERT’s last week, last month’s, and last quarter’s current intraday variation average was a negative 9.43%, a negative 2.11%, and a positive 3.84%.

DIEGEM KENNEDYCERT’s highest amplitude of average volatility was 9.43% (last week), 5.71% (last month), and 3.84% (last quarter).

Volume

Today’s last reported volume for DIEGEM KENNEDYCERT is 1 which is 97.22% below its average volume of 36.

More news about DIEGEM KENNEDYCERT.

6. ABIONYX PHARMA (ABNX.PA)

8.74% Price Change

ABIONYX Pharma SA, a biotech company, discovers and develops therapies for the treatment of renal and ophthalmological diseases. The company is developing CER-001, a negatively-charged lipoprotein particle which contains human recombinant apoA-I, the natural high density lipoprotein (HDL) protein, and sphingomyelin and dipalmitoylphosphatidylglycerol natural phospholipids designed to mimicks the structural and functional biological properties of pre-beta HDL for the treatment of post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia patients; CER-002, a peroxisome proliferator-activated receptor delta specific agonist for the treatment of cardiovascular and metabolic diseases; and CER-209, a drug candidate for the treatment of metabolic diseases in the liver, as well as atherosclerois and non-alcoholic steato-hepatitis. It has a strategic partnership with GTP Biologics and VBI Therapeutics Group for the bioproduction of the bio-HDL in France. The company was formerly known as Cerenis Therapeutics Holding SA and changed its name to ABIONYX Pharma SA in August 2019. ABIONYX Pharma SA was founded in 2005 and is based in Balma, France.

CAC 40 ended the session with ABIONYX PHARMA jumping 8.74% to €1.24 on Monday while CAC 40 rose 0.27% to €7,022.19.

Earnings Per Share

As for profitability, ABIONYX PHARMA has a trailing twelve months EPS of €-0.13.

Yearly Top and Bottom Value

ABIONYX PHARMA’s stock is valued at €1.24 at 22:40 EST, way below its 52-week high of €2.49 and way above its 52-week low of €1.11.

More news about ABIONYX PHARMA.

7. IDEX BIOMETRICS (IDEX.OL)

8.13% Price Change

IDEX Biometrics ASA, together with its subsidiaries, designs, develops, and sells fingerprint authentication solutions in Norway, Europe, the Middle East, Africa, the Americas, and the Asia-Pacific regions. The company's fingerprint authentication solutions are used primarily in contactless financial payment, access control, and smart cards, as well as card-based devices for the storage of digital currencies. It primarily serves manufacturers of smart cards for financial payment applications and biometric payment card markets. The company was incorporated in 1996 and is headquartered in Oslo, Norway.

Oslo Børs Benchmark Index_GI ended the session with IDEX BIOMETRICS jumping 8.13% to €0.52 on Monday, after four successive sessions in a row of gains. Oslo Børs Benchmark Index_GI rose 0.09% to €1,312.00, after two consecutive sessions in a row of gains, on what was a somewhat up trend trading session today.

Earnings Per Share

As for profitability, IDEX BIOMETRICS has a trailing twelve months EPS of kr-0.25.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -141.4%.

More news about IDEX BIOMETRICS.

8. TEKNA HOLDING (TEKNA.OL)

8.12% Price Change

Tekna Holding ASA develops, manufactures, and sells micro and nano powders, and plasma process solutions in North America, Europe, Asia, and internationally. The company offers spherical powders, such as titanium, nickel, and aluminum alloys, as well as tungsten and tantalum; and nanopowders, including nickel nanopowder, silicon nanopowder, copper nanopowder, and boron nitride nanotubes for use in additive manufacturing, metal injection molding, thermal spray, and hot isostatic pressing. It serves aviation, aerospace, medical, mining and drilling, energy storage, and microelectronics industries. The company was founded in 1990 and is headquartered in Sherbrooke, Canada. Tekna Holding ASA is a subsidiary of Arendals Fossekompani ASA.

Oslo Børs Benchmark Index_GI ended the session with TEKNA HOLDING rising 8.12% to €6.92 on Monday while Oslo Børs Benchmark Index_GI jumped 0.09% to €1,312.00.

Earnings Per Share

As for profitability, TEKNA HOLDING has a trailing twelve months EPS of kr-0.91.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -28.94%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 45%, now sitting on 33.18M for the twelve trailing months.

Volatility

TEKNA HOLDING’s last week, last month’s, and last quarter’s current intraday variation average was a negative 2.65%, a negative 1.84%, and a positive 3.08%.

TEKNA HOLDING’s highest amplitude of average volatility was 2.65% (last week), 2.68% (last month), and 3.08% (last quarter).

Sales Growth

TEKNA HOLDING’s sales growth is 11.5% for the current quarter and 62% for the next.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, TEKNA HOLDING’s stock is considered to be overbought (>=80).

More news about TEKNA HOLDING.

9. EBUSCO HOLDING (EBUS.AS)

6.94% Price Change

Ebusco Holding N.V., together with its subsidiaries, develops, manufactures, and distributes zero emission buses, batteries, and charging systems in the Netherlands, Belgium, France, Germany, Norway, Switzerland, and Denmark. It also sells ancillary products and services; and provides electric vehicle ecosystem repair and maintenance services. Ebusco Holding N.V. was founded in 2010 and is headquartered in Deurne, the Netherlands.

AEX-Index ended the session with EBUSCO HOLDING jumping 6.94% to €6.47 on Monday while AEX-Index rose 0.2% to €735.39.

Earnings Per Share

As for profitability, EBUSCO HOLDING has a trailing twelve months EPS of €-1.11.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -20.25%.

More news about EBUSCO HOLDING.

10. HAVILA SHIPPING (HAVI.OL)

5.26% Price Change

Havila Shipping ASA, together with its subsidiaries, engages in the shipping business. It manages and operates offshore service vessels primarily in Norway, the United Kingdom, Denmark, Belgium, the Netherlands, Iceland, Tunisia, the Marshall Islands, and the United States. The company operates a fleet of 17 vessels, including 2 anchor handling vessels, 11 platform supply vessels, 1 rescue recovery vessel, and 3 subsea vessels. Its anchor handling tug and supply vessels are used for moving rigs and putting out anchors, as well as for supply services; platform supply vessels are used to carry goods, water, drilling mud, chemicals, etc. to and from the offshore installations; subsea vessels are used for under water construction work, as well as for support for under water operations; and rescue recovery vessels are used to offer security services, such as oil spill preparedness, fire protection, rescue operation, and recovery at oil installations. The company was founded in 2003 and is headquartered in Fosnavåg, Norway. Havila Shipping ASA is a subsidiary of Havila Holding AS.

Oslo Børs Benchmark Index_GI ended the session with HAVILA SHIPPING rising 5.26% to €9.60 on Monday, after two consecutive sessions in a row of gains. Oslo Børs Benchmark Index_GI rose 0.09% to €1,312.00, after two sequential sessions in a row of gains, on what was a somewhat bullish trend trading session today.

Earnings Per Share

As for profitability, HAVILA SHIPPING has a trailing twelve months EPS of kr-4.64.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -59.03%.

Earnings Before Interest, Taxes, Depreciation, and Amortization

HAVILA SHIPPING’s EBITDA is 44.19.

Volume

Today’s last reported volume for HAVILA SHIPPING is 59272 which is 31.99% below its average volume of 87162.

Revenue Growth

Year-on-year quarterly revenue growth grew by 7.6%, now sitting on 710.34M for the twelve trailing months.

More news about HAVILA SHIPPING.

Losers Today

1. CABKA (CABKA.AS)

-8.07% Price Change

Cabka N.V. manufactures and sells pallets and containers made from recycled plastic in Europe and North America. The company sells its recycled plastic products to blue chip clients in the food and beverage, retail, automotive, dairy, meat and poultry, chemical, pharmaceutical, and pooling industries in approximately 80 countries. Cabka N.V. was incorporated in 1994 and is headquartered in Berlin, Germany.

AEX-Index ended the session with CABKA dropping 8.07% to €7.06 on Monday while AEX-Index rose 0.2% to €735.39.

Earnings Per Share

As for profitability, CABKA has a trailing twelve months EPS of €-1.15.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -37.67%.

Volatility

CABKA’s last week, last month’s, and last quarter’s current intraday variation average was a positive 1.20%, a negative 0.12%, and a positive 3.26%.

CABKA’s highest amplitude of average volatility was 1.20% (last week), 3.93% (last month), and 3.26% (last quarter).

Volume

Today’s last reported volume for CABKA is 5262 which is 20.17% below its average volume of 6592.

Sales Growth

CABKA’s sales growth for the current quarter is 3.2%.

More news about CABKA.

2. ATLANTIC SAPPHIRE (ASA.OL)

-7.47% Price Change

Atlantic Sapphire ASA, together with its subsidiaries, engages in the land-based salmon farming business. It operates through two segments, Fish Farming (Denmark); and Fish Farming (US). The company is involved in the production and sale of salmon. It operates in the United States, Denmark, and internationally. The company was founded in 2010 and is headquartered in Vikebukt, Norway.

Oslo Børs Benchmark Index_GI ended the session with ATLANTIC SAPPHIRE sliding 7.47% to €1.63 on Monday, after five sequential sessions in a row of gains. Oslo Børs Benchmark Index_GI jumped 0.09% to €1,312.00, after two successive sessions in a row of gains, on what was a somewhat bullish trend exchanging session today.

Earnings Per Share

As for profitability, ATLANTIC SAPPHIRE has a trailing twelve months EPS of kr-7.09.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -24.26%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 55.3%, now sitting on 18.95M for the twelve trailing months.

Volume

Today’s last reported volume for ATLANTIC SAPPHIRE is 859166 which is 12.61% below its average volume of 983167.

More news about ATLANTIC SAPPHIRE.

3. NAPATECH (NAPA.OL)

-7.41% Price Change

Napatech A/S offers reconfigurable computing solutions for the networking and cybersecurity applications worldwide. The company provides Link Capture Software that enables packet capture with nanosecond timestamping and replay with precise inter-frame gap control; Link Inline Software, which offers a processing architecture that offloads and accelerates flow aware application data planes; Link Virtualization Software that offloads and accelerates the Open vSwitch data plane to enhance CPU efficiency and network performance; and Link Programmable, which enables end users and OEMs to deploy FPGA computation solutions. It also offers solutions for telecom operators, cloud and data center service providers, and infrastructure and defense, as well as financial services, cyber security, network management, and virtualization. The company was incorporated in 2003 and is headquartered in Copenhagen, Denmark.

Oslo Børs Benchmark Index_GI ended the session with NAPATECH falling 7.41% to €11.25 on Monday, after four sequential sessions in a row of gains. Oslo Børs Benchmark Index_GI rose 0.09% to €1,312.00, after two consecutive sessions in a row of gains, on what was a somewhat bullish trend trading session today.

Earnings Per Share

As for profitability, NAPATECH has a trailing twelve months EPS of kr-1.19.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -57.61%.

More news about NAPATECH.

4. ADOCIA (ADOC.PA)

-6.24% Price Change

Adocia SA, a clinical-stage biotechnology company, researches and develops formulations of pre-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. Its proprietary BioChaperone technological platform provides molecular delivery of therapeutic proteins. The company's clinical product pipeline includes insulin formulations, such as BioChaperone Lispro U100 and U200, which are ultra-rapid formulations based on rapid insulin lispro; BioChaperone Combo, a combination of acting insulin glargine and rapid-acting insulin lispro; BioChaperone LisPram, a combination of prandial insulin with pramlintide; and BioChaperone Glucagon, an aqueous formulation of human glucagon for the treatment of hypoglycemia, as well as M1Pram, a metabolite of insulin glargine and pramlintide. Its preclinical pipeline includes products for the treatment of diabetes and obesity comprising AdoShell Islets, an implant containing islets of Langerhans; AdOral Sema, an oral delivery of semaglutide; and BioChaperone GluExe, a combination of glucagon and exenatide. The company has a strategic alliance with Tonghua Dongbao Pharmaceutical Co., Ltd. to develop and commercialize BioChaperone Lispro and BioChaperone Combo in China and other Asian and Middle Eastern territories. Adocia SA was incorporated in 2005 and is headquartered in Lyon, France.

CAC 40 ended the session with ADOCIA sliding 6.24% to €7.51 on Monday while CAC 40 rose 0.27% to €7,022.19.

Earnings Per Share

As for profitability, ADOCIA has a trailing twelve months EPS of €-2.69.

Moving Average

ADOCIA’s value is way above its 50-day moving average of €4.06 and way higher than its 200-day moving average of €3.59.

Volatility

ADOCIA’s last week, last month’s, and last quarter’s current intraday variation average was a positive 3.68%, a negative 1.18%, and a positive 7.55%.

ADOCIA’s highest amplitude of average volatility was 3.68% (last week), 8.43% (last month), and 7.55% (last quarter).

Revenue Growth

Year-on-year quarterly revenue growth grew by 96.9%, now sitting on 17.36M for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, ADOCIA’s stock is considered to be oversold (<=20).

More news about ADOCIA.

5. LINK MOBILITY GRP (LINK.OL)

-4.91% Price Change

LINK Mobility Group Holding ASA, together with its subsidiaries, provides mobile and communication-platform-as-a-service solutions. It operates through five segments: Northern Europe, Western Europe, Central Europe, Northern America, and Global Messaging. The company offers mission-critical customer engagement solutions, such as Enterprise Omnichannel Notification System, and API-driven communication for email, A2P SMS, and voice communication services. It also provides Xenioo, a platform to automate conversations between companies and people across a range of text and voice channels; a marketing platform that offers customer engagement, marketing automation, and email and SMS marketing services; long numbers that sends and receives messages; and short codes, a memorable short mobile numbers to allow inbound communications to flow. Its solutions are used in baking and finance, retail and ecommerce, logistics, advertising and marketing, travel and tourism, healthcare, and government and public sector industries. The company was founded in 2001 and is headquartered in Oslo, Norway.

Oslo Børs Benchmark Index_GI ended the session with LINK MOBILITY GRP sliding 4.91% to €12.02 on Monday, following the last session’s upward trend. Oslo Børs Benchmark Index_GI jumped 0.09% to €1,312.00, after two sequential sessions in a row of gains, on what was a somewhat bullish trend trading session today.

Earnings Per Share

As for profitability, LINK MOBILITY GRP has a trailing twelve months EPS of kr-0.69.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -3.69%.

Earnings Before Interest, Taxes, Depreciation, and Amortization

LINK MOBILITY GRP’s EBITDA is 47.78.

Moving Average

LINK MOBILITY GRP’s value is below its 50-day moving average of kr13.27 and higher than its 200-day moving average of kr11.00.

Volume

Today’s last reported volume for LINK MOBILITY GRP is 429475 which is 45.15% below its average volume of 783009.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, LINK MOBILITY GRP’s stock is considered to be oversold (<=20).

More news about LINK MOBILITY GRP.

6. PHOTOCURE (PHO.OL)

-4.75% Price Change

Photocure ASA, a specialty pharmaceutical company, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products in Nordic countries, Germany, France, Austria, the United Kingdom, the BeNeLux, Italy, other European Countries, Canada, and the United States. The company offers Hexvix/Cysview for the detection and management of bladder cancer. It also develops Cevira for the treatment of human papilloma virus infection and precancerous lesions of the cervix. The company sells its products to pharmaceutical wholesalers, pharmacies, and hospitals through license partners. Photocure ASA was founded in 1993 and is headquartered in Oslo, Norway.

Oslo Børs Benchmark Index_GI ended the session with PHOTOCURE dropping 4.75% to €58.10 on Monday while Oslo Børs Benchmark Index_GI rose 0.09% to €1,312.00.

Earnings Per Share

As for profitability, PHOTOCURE has a trailing twelve months EPS of kr-1.45.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -8.24%.

Yearly Top and Bottom Value

PHOTOCURE’s stock is valued at kr58.10 at 22:40 EST, way below its 52-week high of kr115.00 and way above its 52-week low of kr40.70.

More news about PHOTOCURE.

7. OCEANTEAM (OTS.OL)

-4.61% Price Change

Oceanteam ASA operates as a subsea and offshore services company in Europe. It provides equipment for offshore cable laying, umbilical installations, and on- and offshore storage and transport. The company also rents turntables, tensioners, reels, demountable turntable systems, and other cable handling and storage equipment, as well as offers cable and umbilical storage, and handling solutions. It serves renewable energy, and oil and gas industries. The company was formerly known as Oceanteam Shipping ASA and changed its name to Oceanteam ASA in December 2015. Oceanteam ASA was incorporated in 2005 and is headquartered in Bærum, Norway.

Oslo Børs Benchmark Index_GI ended the session with OCEANTEAM sliding 4.61% to €1.45 on Monday while Oslo Børs Benchmark Index_GI jumped 0.09% to €1,312.00.

Earnings Per Share

As for profitability, OCEANTEAM has a trailing twelve months EPS of kr-0.32.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -13.62%.

Moving Average

OCEANTEAM’s value is way under its 50-day moving average of kr1.61 and under its 200-day moving average of kr1.58.

Revenue Growth

Year-on-year quarterly revenue growth grew by 33.3%, now sitting on 70k for the twelve trailing months.

Volume

Today’s last reported volume for OCEANTEAM is 54434 which is 178.79% above its average volume of 19525.

Yearly Top and Bottom Value

OCEANTEAM’s stock is valued at kr1.45 at 22:40 EST, way below its 52-week high of kr2.18 and way above its 52-week low of kr1.26.

More news about OCEANTEAM.

8. IEP INVEST (IEP.BR)

-4.39% Price Change

Iep Invest, NV is an investment firm specializing in investments in and loans to real estate companies. The firm previously operated as manufacturing group. It was formerly known as Punch International nv and changed its name to Iep Invest, NV in May 2014. Iep Invest, NV was founded in 1982 and is based in Antwerp, Belgium.

BEL 20 ended the session with IEP INVEST sliding 4.39% to €5.45 on Monday while BEL 20 jumped 0.31% to €3,518.40.

Earnings Per Share

As for profitability, IEP INVEST has a trailing twelve months EPS of €-0.22.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -2.4%.

Yearly Top and Bottom Value

IEP INVEST’s stock is valued at €5.45 at 22:40 EST, below its 52-week high of €5.90 and way higher than its 52-week low of €4.84.

Revenue Growth

Year-on-year quarterly revenue growth grew by 1.8%, now sitting on 7.15M for the twelve trailing months.

Volume

Today’s last reported volume for IEP INVEST is 25 which is 96.09% below its average volume of 640.

Volatility

IEP INVEST’s last week, last month’s, and last quarter’s current intraday variation average was 0.46%, 0.06%, and 2.76%.

IEP INVEST’s highest amplitude of average volatility was 3.21% (last week), 3.75% (last month), and 2.76% (last quarter).

More news about IEP INVEST.

9. MITHRA (MITRA.BR)

-4.2% Price Change

Mithra Pharmaceuticals SA develops, manufactures, and markets complex therapeutics in the areas of contraception, menopause, and hormone-dependent cancers in Belgium, Europe and internationally. Its development candidates include Estelle, a combined oral contraceptive that has completed phase III clinical trial; Donesta, which is in phase III clinical trial for estetrol-based oral hormone treatment; and products for neuroprotection and wound healing. The company also develops Myring, a contraceptive vaginal ring releasing a combination of hormones; Tibelia, a tablet composed of tibolone and a synthetic steroid used for hormone therapy in menopause; and Zoreline, a biodegradable subcutaneous implant for use in prostate and breast cancers, and benign gynecological indications. In addition, it provides products in polymeric forms, implants, sterile injectable products, and hormonal tablets. The company was founded in 1999 and is headquartered in Liège, Belgium.

BEL 20 ended the session with MITHRA falling 4.2% to €1.10 on Monday, after three sequential sessions in a row of losses. BEL 20 rose 0.31% to €3,518.40, after two successive sessions in a row of losses, on what was a somewhat up trend exchanging session today.

Earnings Per Share

As for profitability, MITHRA has a trailing twelve months EPS of €-1.36.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -575.59%.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, MITHRA’s stock is considered to be overbought (>=80).

Yearly Top and Bottom Value

MITHRA’s stock is valued at €1.10 at 22:40 EST, under its 52-week low of €1.11.

Revenue Growth

Year-on-year quarterly revenue growth declined by 38.1%, now sitting on 62.67M for the twelve trailing months.

More news about MITHRA.

10. SEQUANA MEDICAL (SEQUA.BR)

-4.17% Price Change

Sequana Medical NV develops and commercializes treatment of fluid overload in liver disease, cancer, and heart failure. The company's products include alfapump system, an implantable pump system for the treatment of refractory liver ascites and malignant ascites; Direct Sodium Removal (DSR) for the treatment of persistent congestion due to heart failure; and alfapump DSR, a fully implanted system for direct sodium removal therapy in patients with fluid overload due to heart failure. It operates in Belgium, Germany, France, Switzerland, and internationally. The company was founded in 2006 and is headquartered in Ghent, Belgium.

BEL 20 ended the session with SEQUANA MEDICAL falling 4.17% to €2.53 on Monday while BEL 20 jumped 0.31% to €3,518.40.

Earnings Per Share

As for profitability, SEQUANA MEDICAL has a trailing twelve months EPS of €-1.39.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -690.43%.

Volatility

SEQUANA MEDICAL’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.10%, a negative 1.28%, and a positive 2.52%.

SEQUANA MEDICAL’s highest amplitude of average volatility was 2.87% (last week), 2.22% (last month), and 2.52% (last quarter).

Yearly Top and Bottom Value

SEQUANA MEDICAL’s stock is valued at €2.53 at 22:40 EST, under its 52-week low of €2.75.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, SEQUANA MEDICAL’s stock is considered to be oversold (<=20).

More news about SEQUANA MEDICAL.

Stay up to date with our winners and losers daily report